Editors' Note: Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial

被引：0
|
作者：
Galetta, Steven
Ganesh, Aravind
Lewis, Ariane
Siegler, James E., III
机构：
来源：
NEUROLOGY | 2022年 / 99卷 / 06期
关键词：
D O I：
10.1212/WNL.0000000000201001
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：258 / 258
页数：1
相关论文
共 33 条
  • [21] Long-term safety and efficacy of memantine treatment in moderate to severe Alzheimer's disease: Results from a three-year trial
    Tariot, Pierre
    Aupperle, Peter
    Safirstein, Beth
    Graham, Stephen
    Lee, Grace
    Tocco, Michael
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S198 - S198
  • [22] Safety and Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion for Parkinson's disease: Three-Year Data from the Open-Label BeyoND study
    Ellenbogen, Aaron
    Adar, Liat
    Salin, Laurence
    Case, Ryan
    Yardeni, Tamar
    Espay, Alberto
    NEUROLOGY, 2023, 100 (17)
  • [23] Three-year follow-up of a randomized multicenter trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson's disease
    Odekerken, V. J.
    van den Mucnkhoff, P.
    Schuurman, P. R.
    de Bie, R. M.
    MOVEMENT DISORDERS, 2014, 29 : S447 - S447
  • [24] Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial
    Johnson, Aileen C.
    Karadkhele, Geeta M.
    Shenvi, Neeta
    Easley, Kirk A.
    Larsen, Christian P.
    Badell, I. Raul
    TRANSPLANTATION DIRECT, 2023, 9 (03): : E1449
  • [25] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
    Ascierto, Paolo A.
    Long, Georgina V.
    Robert, Caroline
    Brady, Benjamin
    Dutriaux, Caroline
    Di Giacomo, Anna Maria
    Mortier, Laurent
    Hassel, Jessica C.
    Rutkowski, Piotr
    McNeil, Catriona
    Kalinka-Warzocha, Ewa
    Savage, Kerry J.
    Hernberg, Micaela M.
    Lebbe, Celeste
    Charles, Julie
    Mihalcioiu, Catalin
    Chiarion-Sileni, Vanna
    Mauch, Cornelia
    Cognetti, Francesco
    Ny, Lars
    Arance, Ana
    Svane, Inge Marie
    Schadendorf, Dirk
    Gogas, Helen
    Saci, Abdel
    Jiang, Joel
    Rizzo, Jasmine
    Atkinson, Victoria
    JAMA ONCOLOGY, 2019, 5 (02) : 187 - 194
  • [26] Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial
    Gupta, Nikhil
    Rogers, Tyson
    Holland, Bradley
    Helo, Sevann
    Dynda, Danuta
    McVary, Kevin T.
    JOURNAL OF UROLOGY, 2018, 200 (02): : 405 - 413
  • [27] Impact of Left Ventricular Dysfunction and Multi-Vessel Disease After Primary Percutaneous Coronary Intervention: Three-Year Outcomes from the HORIZONS-AMI Trial
    Daneault, Benoit
    Genereux, Philippe
    Kirtane, Ajay
    Witzenbichler, Bernhard
    Guagliumi, Giulio
    Paradis, Jean-Michel
    Fahy, Martin
    Mehran, Roxana
    Stone, Gregg
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B138 - B139
  • [28] Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial (vol 5, pg 187, 2018)
    Ascierto, P. A.
    Long, G., V
    Robert, C.
    JAMA ONCOLOGY, 2019, 5 (02) : 271 - 271
  • [29] AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort in Open-Label Dose Evaluation Study SUNRISE-PD at 6 Months Post Administration
    Corcoran, Gavin
    Karunakara, Ajith
    Vaughn, Ben
    Brand-Schieber, Elimor
    Foltynie, Thomas
    Barker, Roger A.
    Palfi, Stephane
    MOLECULAR THERAPY, 2021, 29 (04) : 84 - 85
  • [30] Three-Year Safety, Tolerability, and Health- Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Shepherd, Frances A.
    de Marinis, Filippo
    Kato, Terufumi
    Wang, Qun
    Su, Wu-Chou
    Choi, Jin Hyuk
    Sriuranpong, Virote
    Melotti, Barbara
    Fidler, Mary J.
    Chen, Jun
    Albayaty, Muna
    Stachowiak, Marta
    Taggart, Sarah
    Wu, Yi-Long
    Tsuboi, Masahiro
    Herbst, Roy S.
    Majem, Margarita
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1209 - 1221
1234